IRBM has developed and optimized biochemical and cell-based assays to support hit identification and lead optimization campaigns for multiple targets across several therapeutic areas including oncology, antivirals, cardiovascular, neurodegeneration and rare diseases. To drive drug design and answer fundamental biological questions, our goal is to generate a measurable signal in response to a change in a biological system.
INITIALLY WE WILL:
- Identify the most suitable biological model and assay technology to align relevance and realization time
- Validate the assay and provide guidance on how to best interpret the results
We’ll use this information to design the best strategy for your target and program.
At IRBM we have developed and optimized a range of biochemical and cellular assays to critically assess how molecules affect biochemical pathways within cells and the interactions between cells.
FOR BIOCHEMICAL ASSAYS, WE CAN FOLLOW
- protein-protein interactions, including peptide-protein complexes and large macromolecular complexes
FOR CELL-BASED ASSAYS WE CAN PROVIDE:
- target distal readouts:
- sub-cellular localization (via split reporter)
- pathway activation (via immunoassays), transcriptional readouts (via reporter assays or qRT-PCR)
- Functional/Phenotypic readouts:
- Cell cycle (via cytometry)
- cell proliferation (metabolic and imaging readouts)
- differentiation (imaging and cytometry)
- cellular trafficking (via imaging)
- metabolic activity (metabolic assays)
- morphology (imaging)
In addition to our comprehensive cell bank that includes all common laboratory lines, we have extensive experience in handling a range of cell types including:
COMPLEX CO- AND
MIXED- CELLULAR ASSAYS:
- Astrocytes-neurons
- Blood-brain barrier models
- Spheroids